226 related articles for article (PubMed ID: 34624820)
1. Discovery of 5-methylpyrimidopyridone analogues as selective antimycobacterial agents.
Wu Y; Cheung CY; Zhou Y; Wang Z; Tu Z; Cook GM; Lu X
Bioorg Med Chem; 2021 Nov; 49():116426. PubMed ID: 34624820
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and antimycobacterial evaluation of novel adamantane and adamantanol analogues effective against drug-resistant tuberculosis.
Alsayed SSR; Lun S; Payne A; Bishai WR; Gunosewoyo H
Bioorg Chem; 2021 Jan; 106():104486. PubMed ID: 33276981
[TBL] [Abstract][Full Text] [Related]
3. QSAR-driven design, synthesis and discovery of potent chalcone derivatives with antitubercular activity.
Gomes MN; Braga RC; Grzelak EM; Neves BJ; Muratov E; Ma R; Klein LL; Cho S; Oliveira GR; Franzblau SG; Andrade CH
Eur J Med Chem; 2017 Sep; 137():126-138. PubMed ID: 28582669
[TBL] [Abstract][Full Text] [Related]
4. Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.
Pieroni M; Wan B; Zuliani V; Franzblau SG; Costantino G; Rivara M
Eur J Med Chem; 2015 Jul; 100():44-9. PubMed ID: 26071857
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel antitubercular 1,5-dimethyl-2-phenyl-4-([5-(arylamino)-1,3,4-oxadiazol-2-yl]methylamino)-1,2-dihydro-3H-pyrazol-3-one analogues.
Ahsan MJ; Samy JG; Jain CB; Dutt KR; Khalilullah H; Nomani MS
Bioorg Med Chem Lett; 2012 Jan; 22(2):969-72. PubMed ID: 22197387
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, biological evaluation, and SAR study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis: part 2. Synthesis of rigid pyrazolones.
Castagnolo D; Manetti F; Radi M; Bechi B; Pagano M; De Logu A; Meleddu R; Saddi M; Botta M
Bioorg Med Chem; 2009 Aug; 17(15):5716-21. PubMed ID: 19581099
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel nitrogenous heterocyclic-containing quinoxaline-1,4-di-N-oxides as potent activator of autophagy in M.tb-infected macrophages.
Zhang H; Lu Q; Zhang J; Qu W; Xie S; Huang L; Yuan Z; Pan Y
Eur J Med Chem; 2021 Nov; 223():113657. PubMed ID: 34217060
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of alkynylated 1,2,4-oxadiazole/1,2,3-1H-triazole glycoconjugates: Discovering new compounds for use in chemotherapy against lung carcinoma and Mycobacterium tuberculosis.
Melo de Oliveira VN; Flávia do Amaral Moura C; Peixoto ADS; Gonçalves Ferreira VP; Araújo HM; Lapa Montenegro Pimentel LM; Pessoa CDÓ; Nicolete R; Versiani Dos Anjos J; Sharma PP; Rathi B; Pena LJ; Rollin P; Tatibouët A; Nascimento de Oliveira R
Eur J Med Chem; 2021 Aug; 220():113472. PubMed ID: 33940463
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, structure, and antimycobacterial activity of 6-[1(3H)-isobenzofuranylidenemethyl]purines and analogs.
Braendvang M; Bakken V; Gundersen LL
Bioorg Med Chem; 2009 Sep; 17(18):6512-6. PubMed ID: 19709890
[TBL] [Abstract][Full Text] [Related]
11. Discovery and evaluation of novel nitrodihydroimidazooxazoles as promising anti-tuberculosis agents.
Tao X; Gao C; Huang ZG; Luo W; Liu KL; Peng CT; Ding CZ; Li J; Chen SH; Yu LT
Bioorg Med Chem Lett; 2019 Sep; 29(17):2511-2515. PubMed ID: 31353295
[TBL] [Abstract][Full Text] [Related]
12.
Deb PK; Al-Shar'i NA; Venugopala KN; Pillay M; Borah P
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):869-884. PubMed ID: 34060396
[TBL] [Abstract][Full Text] [Related]
13. Antimycobacterial activity of novel 1-(5-cyclobutyl-1,3-oxazol-2-yl)-3-(sub)phenyl/pyridylthiourea compounds endowed with high activity toward multidrug-resistant Mycobacterium tuberculosis.
Sriram D; Yogeeswari P; Dinakaran M; Thirumurugan R
J Antimicrob Chemother; 2007 Jun; 59(6):1194-6. PubMed ID: 17449482
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity.
Martins F; Santos S; Ventura C; Elvas-Leitão R; Santos L; Vitorino S; Reis M; Miranda V; Correia HF; Aires-de-Sousa J; Kovalishyn V; Latino DA; Ramos J; Viveiros M
Eur J Med Chem; 2014 Jun; 81():119-38. PubMed ID: 24836065
[TBL] [Abstract][Full Text] [Related]
15. Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents.
Ng PS; Manjunatha UH; Rao SP; Camacho LR; Ma NL; Herve M; Noble CG; Goh A; Peukert S; Diagana TT; Smith PW; Kondreddi RR
Eur J Med Chem; 2015 Dec; 106():144-56. PubMed ID: 26544629
[TBL] [Abstract][Full Text] [Related]
16. 6-Fluorophenylbenzohydrazides inhibit Mycobacterium tuberculosis growth through alteration of tryptophan biosynthesis.
Consalvi S; Venditti G; Zhu J; Boshoff HI; Arora K; De Logu A; Ioerger TR; Rubin EJ; Biava M; Poce G
Eur J Med Chem; 2021 Dec; 226():113843. PubMed ID: 34520959
[TBL] [Abstract][Full Text] [Related]
17. Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity.
Panda M; Ramachandran S; Ramachandran V; Shirude PS; Humnabadkar V; Nagalapur K; Sharma S; Kaur P; Guptha S; Narayan A; Mahadevaswamy J; Ambady A; Hegde N; Rudrapatna SS; Hosagrahara VP; Sambandamurthy VK; Raichurkar A
J Med Chem; 2014 Jun; 57(11):4761-71. PubMed ID: 24818517
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of indolopyridone hybrids as new antituberculosis agents.
Rather MA; Rasool F; Bhat ZS; Dar HU; Maqbool M; Amin S; Yousuf SK; Ahmad Z
Microb Pathog; 2017 Dec; 113():330-334. PubMed ID: 29079215
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and evaluation of new 2-(quinoline-4-yloxy)acetamide-based antituberculosis agents.
Borsoi AF; Paz JD; Abbadi BL; Macchi FS; Sperotto N; Pissinate K; Rambo RS; Ramos AS; Machado D; Viveiros M; Bizarro CV; Basso LA; Machado P
Eur J Med Chem; 2020 Apr; 192():112179. PubMed ID: 32113048
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and in-vitro antimycobacterial evaluation of 1-(cyclopropyl/2,4-difluorophenyl/tert-butyl)-1,4-dihydro- 8-methyl-6-nitro-4-oxo-7-(substituted secondary amino)quinoline-3-carboxylic acids.
Senthilkumar P; Dinakaran M; Chandraseakaran Y; Yogeeswari P; Sriram D
Arch Pharm (Weinheim); 2009 Feb; 342(2):100-12. PubMed ID: 19137533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
